Human clinical trials may begin on an antiviral compound which was discovered and developed by Emory University and shows promise as a potential treatment for COVID-19.
The U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application by Drug Innovation Ventures at Emory (DRIVE), LLC, wholly owned by Emory University, for EIDD-2801. The antiviral compound, which can be taken by mouth, is exclusively licensed to Ridgeback Biotherapeutics, LP (Ridgeback), a closely held biotechnology company. The FDA's approval allows Ridgeback to initiate human clinical testing in the United States.
“We are thankful to FDA Commissioner Dr. Steven Hahn and his team at the Anti-Viral Division for the unprecedented speed in reviewing our submission, the guidance and the highly collaborative process that ensures this promising drug can advance into the clinical development as fast as possible,” says Wendy Holman, chief executive officer of Ridgeback.
“We also appreciate the guidance we have received from the Assistant Secretary of Preparedness and Response (ASPR), including discussions that occurred months before COVID-19 first emerged, to help Emory/DRIVE advance the development of EIDD-2801 as quickly as possible to address this global pandemic," Holman adds.
EIDD-2801 prevents the replication of SARS-CoV-2, the virus that causes COVID-19. It has shown potent activity against SARS-CoV and MERS-CoV in animal models of infection. In addition to coronaviruses, EIDD-2801 has broad spectrum activity against a number of diseases of public health concern, including influenza, chikungunya, Ebola and equine encephalitis (VEE and EEE).
The antiviral is orally available and, in addition to COVID-19, is being developed for the treatment of seasonal and pandemic influenza under a contract awarded to Emory Institute for Drug Development by the National Institute of Allergy and Infectious Diseases (NIAID) and for Venezuelan and Eastern equine encephalitis virus (VEEV and EEEV) by the Defense Threat Reduction Agency (DTRA).
“FDA’s prompt approval of our IND allows us to initiate human testing for EIDD-2801 as quickly as possible,” says George Painter, PhD, director of the Emory Institute for Drug Development (EIDD) and CEO of DRIVE. “We are grateful to our collaborators for helping us to assemble this application quickly, and to the FDA for expediting the process. An orally available antiviral medication would be a critical weapon for fighting COVID-19.”
Ridgeback and DRIVE have established a partnership to advance EIDD-2801 through clinical development and to optimize availability during the current COVID-19 pandemic. EIDD-2801 was exclusively licensed to Ridgeback in March 2020.
"We look forward to our continued work with the highly experienced drug development team at DRIVE and the dedicated medical, public health and governmental personnel who are on the frontlines of this pandemic — in the United States and abroad,” Holman says. “The ability to deliver promising treatments to patients in need is what makes us excited to come to work every day. Ridgeback brings its unique perspective, honed by our success developing an Ebola antiviral during an outbreak in the Congo, to help advance EIDD-2801 for the treatment of diseases that are critical to pandemics and global health."
Skip past news feed